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Alveolar macrophage activity and the pulmonary
complications of haematopoietic stem cell
transplantation
A T Whittle, M Davis, C L Shovlin, P S Ganly, C Haslett, A P Greening
Abstract
Background—The success of haematopoi-
etic (bone marrow or peripheral blood)
stem cell transplantation (SCT) is com-
promised by pulmonary complications.
We hypothesised that a proinflammatory
alveolar microenvironment, reflected in
alveolar macrophage (AM) cytokine pro-
duction, would predispose to such compli-
cations.
Methods—AM were isolated from adult
SCT recipients by bronchoalveolar lavage
before SCT (n=32) and during post-
transplant pancytopenia (n=23). Concen-
trations of tumour necrosis factor
(TNF)á, granulocyte-macrophage colony
stimulating factor (GM-CSF), interleukin
(IL)-1â, IL-6, and IL-8 in 24 hour AM cul-
ture medium were measured by enzyme
linked immunosorbent assay and com-
pared with both the occurrence of post-
SCT lung disease and with subjects’
previous respiratory histories.
Results—Eleven subjects developed lung
disease within 6 months of SCT. These
subjects had higher median pre-
transplant AM TNFá (8 (IQR 1–8) v 2
(1–5) ng/106AM, p=0.01,median diVerence
(D) = 3, 95% CI 0.1 to 7), GM-CSF (5
(0.7–8) v 0.2 (0.1–0.8), p=0.006, D = 4, 95%
CI 0.5 to 7), and IL-6 (0.5 (0.1–1) v 0.1
(0.02–0.3), p=0.049, D = 0.3, 95% CI 0.0002
to 1) production than remaining subjects;
IL-1â and IL-8 did not diVer. During pan-
cytopenia high AM GM-CSF production
again predicted later lung disease (1
(0.7–9) v 0.1 (0.06–0.3), p=0.01, D = 1, 95%
CI 0.1 to 6). A history of recent chest dis-
ease was associated with high AM TNFá
and GM-CSF production and with post-
SCT lung disease. Pre-SCT lung function
was unrelated to post-SCT lung disease.
Conclusions—Recent respiratory disease
and persistent proinflammatory AM be-
haviour detectable before transplantation
are associated with lung disease following
SCT. These associations may prove useful
in pre-transplant risk assessment.
(Thorax 2001;56:941–946)
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Marrow ablative cytotoxic therapy with autolo-
gous or allogeneic haematopoietic stem cell
rescue (bone marrow or peripheral blood stem
cell transplantation, SCT) is used increasingly
in adults to treat haematological malignancy,
solid tumours, and severe autoimmune dis-
ease,1 2 but complications of the procedure
limit its use. Lung diseases (infective, inflam-
matory, or idiopathic) are among the common-
est complications: 11–60% of recipients de-
velop lung disease following transplantation.
The incidence varies according to transplant
type and underlying disease, but reported case
mortality is 40–60%.3–5 A technique allowing
pre-transplant estimation of the risk of post-
transplant lung disease would therefore be
clinically valuable.
In recipients of allogeneic bone marrow
transplants, impaired gas transfer and in-
creased bronchoalveolar lavage (BAL) fluid
albumin levels before transplantation are asso-
ciated with post-transplant pulmonary disease
and mortality.6 7 These measures were not pre-
dictive in individual cases, but the observations
suggest that alveolar abnormalities before SCT
may predispose to subsequent lung disease. We
hypothesised that this predisposition may be
detectable as proinflammatory alveolar im-
mune cell behaviour. Unlike other alveolar
immune cells, the resident alveolar macro-
phages (AM) survive marrow ablative cytotoxic
therapy and persist for up to 90 days after allo-
geneic SCT.8 9 We compared the proinflamma-
tory behaviour of AM obtained from SCT
recipients before transplantation and during
post-transplant pancytopenia with the patients’
clinical progress.
AM activity was defined using a panel of well
characterised proinflammatory cytokines pro-
duced by AM and involved in infectious and
inflammatory lung diseases: tumour necrosis
factor á (TNFá), granulocyte-macrophage
colony stimulating factor (GM-CSF), and
interleukins (IL)-1â, IL-6, and IL-8.10–12
Methods
STUDY DESIGN
This prospective study was approved by
Lothian health ethics committee. Adult pa-
tients attending Edinburgh’s Western General
Hospital Bone Marrow Transplant Unit for
SCT were eligible; patients were excluded if
the responsible clinicians judged them unfit for
bronchoscopy and BAL. With informed writ-
ten consent, subjects underwent fibreoptic
bronchoscopy and BAL before starting the
cytotoxic transplant conditioning regimen (B1)
and again at the nadir of post-transplant
pancytopenia (B2). Subjects were observed for
new lung disease for 6 months after SCT.
Proinflammatory cytokine production by AM
from each specimen of BAL fluid was assayed
by a researcher blind to the subjects’ clinical
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progress and compared with the occurrence of
post-transplant lung disease. Data from sub-
jects with clinically apparent lung disease at the
time of BAL were excluded from the analysis.
The recent respiratory history and pulmonary
function of each subject were compared with
AM cytokine production and with post-
transplant lung disease.
CLINICAL ASSESSMENT
The history, examination, chest radiograph,
and pulmonary function were recorded before
transplantation. The following aspects of respi-
ratory history were regarded as relevant:
current tobacco smoking, respiratory symp-
toms in the month before B1, chest disease
requiring continuing treatment such as asthma
or with residual abnormalities of chest radio-
graphy or lung function, documented paren-
chymal lung disease such as infection since the
diagnosis of malignant disease. Pulmonary
function tests included forced expiratory vol-
ume in 1 second (FEV1) and forced vital
capacity (FVC) by wedge bellows spirometry
(Vitalograph, Buckinghamshire, UK), total
lung capacity (TLC) by steady state helium
dilution (P K Morgan, Kent, UK), and single
breath carbon monoxide transfer factor and
coeYcient (TLCO and KCO, P K Morgan).
Post-transplant lung disease was defined by
new radiographic opacification, or sustained
tachypnoea (>25 breaths/min) with a fall in
oxygen saturation (SaO2) of >5% from baseline
on two consecutive readings, occurring within
6 months of transplantation. Changes due to
proven recurrent malignancy were excluded.
Lung disease was sought by daily assessment
while subjects were in hospital, by questioning
at clinic attendances, and by medical record
review at the end of the study.
BRONCHOALVEOLAR LAVAGE
Fibreoptic bronchoscopy was performed under
sedation and local anaesthesia. Thrombocyto-
penic patients (platelets <40 × 109/l) received
platelets before bronchoscopy. The middle
lobe or lingula was lavaged with up to 240 ml
normal saline at 37°C, with gentle aspiration
after each 30 ml aliquot. Details of the
methods and complications of bronchoscopy
and BAL in this study are reported elsewhere.13
CYTOKINE ASSAYS
Lavage fluid was filtered through gauze. Cells
were pelleted at 1000 rpm, resuspended in
medium 199 (Gibco BRL, Paisley, UK), and
counted under direct light microscopy. AM
were isolated by adhesion to culture plates over
1 hour at 37°C. Floating cells were counted
and discarded; adherent AM were re-incubated
in RPMI-1640 medium (Gibco BRL) with 5%
fetal calf serum (FCS) for 22 hours at 37°C.
The AM number was defined as the initial cell
count minus the floating cells. After incubation
the medium was spun to remove cell debris
(1000 rpm) then stored at –80°C. Cytokine
levels in this medium were assayed in a single
batch using in house sandwich enzyme linked
immunosorbent assays (ELISA).
ELISA used the following incubations with
100 µl reagent/well on microtitre plates (Im-
mulon 1B, Dynex, Chantilly, Virginia, USA).
Plates were washed three times after each step
with 0.05% Tween 20 in phosphate buVered
saline: (1) 3 hours at 37°C with monoclonal
mouse anti-human cytokine antibody (Gen-
zyme, Cambridge, Massachusetts, USA or
anti-TNFá, Immunogenetics, Belgium) in
ELISA coating solution (KPL, Gaithersburg,
Maryland, USA); (2) 1 hour at 37°C with
blocking buVer (BSA diluent/blocking solu-
tion, KPL); (3) 18 hours at 4°C with duplicate
aliquots of AM supernatant diluted both 5-fold
and 20-fold in RPMI/FCS. Each plate also
included log dilutions between 7.8 and
1000 pg/ml of standard cytokine solutions
(Genzyme) for calibration, plus blocking buVer
and blank negative controls; (4) 3 hours at
18°C with polyclonal rabbit (goat for IL-8)
anti-human cytokine antibody (Genzyme) in
blocking buVer; (5) 3 hours at 18°C with alka-
line phosphatase conjugated donkey anti-
rabbit or anti-goat IgG antibody (Jackson
ImmunoResearch, West Grove, Pennsylvania,
USA) in blocking buVer; (6) 1 hour at 18°C
with 1 mg/ml phosphatase substrate (Sigma
104, Sigma-Aldrich, Poole, UK) in 10%
diethanol amine buVer.
The results were read at 405 nm on an auto-
mated spectrophotometric ELISA reader. Un-
detectable cytokine levels were ascribed the
value of the lower detection limit of the assay
(10 pg/ml). Cytokine concentrations were ad-
justed according to the number of adherent
AM/ml culture supernatant.
DATA ANALYSIS
Normally distributed results are quoted as
mean (SD) values and were compared with the
two tailed Student’s t test. Other results are
quoted as median (interquartile range) values
and were compared by the Mann-Whitney
rank sum test. Categories were compared by
the ÷2 test. Statistical calculations were per-
formed with Sigma-Stat for windows 1.0 (Jan-
del Corporation, Erkrath, Germany). Relative
risks and median diVerences with confidence
intervals were calculated by recommended
methods.14 15
Results
SUBJECTS
Of 60 eligible patients, five were unfit for BAL
and 21 withheld consent, giving a study popu-
lation of 34 (table 1). One B1 was unsuccessful
and one subject was unavailable for B1, so 32
B1 procedures performed a median of 9 (range
1–32) days before transplantation are analysed.
Six subjects withheld consent for B2 and four
had lung disease, so 24 procedures performed a
median of 6 (3–11) days after transplantation
are analysed.
As transplant conditioning, 32 subjects
received agents which have been implicated in
lung toxicity: total body irradiation (10–12 Gy,
n=4), melphalan (120–200 mg/m2, n=16),
cyclophosphamide (4–8 g/m2, n=15) carmus-
tine (BCNU, 300 mg/m2, n=8), and busulphan
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(600 mg/m2, n=4).16–19 Ten diVerent condition-
ing regimens were used; because of this variety,
their eVects on post-transplant lung disease
have not been analysed.
LUNG DISEASE
Eleven subjects (median age 44 years, 5
women; 10 B1 subjects and five B2 subjects)
developed lung disease within 6 months of
SCT with two fatalities (table 2). The under-
lying diagnoses and transplant types of these
subjects were similar to the total study popula-
tion: breast cancer (n=2), non-Hodgkin’s
lymphoma (n=2), Hodgkin’s disease (n=1),
myeloma (n=2), chronic myeloid leukaemia
(n=1), acute leukaemia (n=2), aplastic anae-
mia (n=1); autologous peripheral blood SCT
(n=7), autologous bone marrow SCT (n=2),
allogeneic SCT (n=2).
ALVEOLAR MACROPHAGE ACTIVITY
AM obtained before transplantation (B1) from
subjects who developed post-transplant lung
disease showed higher median TNFá, GM-
CSF, and IL-6 production than those from
subjects who did not develop disease (table 3).
IL-1â showed a trend in this direction but IL-8
production did not diVer between the groups.
High B1 TNFá and GM-CSF production were
strong predictors of lung disease in a categori-
cal analysis using cut oV criteria chosen retro-
spectively. All six subjects with pre-transplant
TNFá production >7 ng/106 AM developed
post-SCT lung disease (p<0.0001, relative risk
(RR) 6.5, 95% confidence interval (CI) 2.6 to
16, fig 1A), as did seven of nine subjects with
pre-transplant GM-CSF production >2 ng/106
AM (p=0.0004, RR 6.0, 95% CI 2.0 to 18, fig
1B).
AM obtained during post-SCT pancytope-
nia (B2) displayed similar profiles, although the
data were weakened by the smaller number of
subjects at this time point. Subjects who later
developed lung disease showed higher B2 AM
GM-CSF production; there was a similar but
non-significant trend in TNFá production
(table 3). Production of IL-1â, IL-6, and IL-8
at B2 did not diVer between the groups. Apply-
ing the criteria used in the pre-transplant
analysis, two of five subjects with B2 TNFá
production >7 ng/106 AM later developed lung
disease (NS, fig 2A), as did both subjects with
B2 GM-CSF production >2 ng/106 AM
(p=0.004, RR 7.3, 95% CI 2.6 to 21, fig 2B).
RESPIRATORY HISTORY AND PULMONARY
FUNCTION
Sixteen subjects gave a relevant respiratory his-
tory (table 2). This was a risk factor for
post-SCT lung disease: nine (56%) developed
respiratory disease compared with two of 18
remaining subjects (11%, p=0.005, RR 5.1,
95% CI 1.3 to 20). However, B1 AM from
subjects with a relevant history did not show
higher median cytokine production than the
remainder (respiratory history (n=15): median
(interquartile range) TNFá 1.19 (1.0–8.2) ng/
106 AM, GM-CSF 0.68 (0.09–8.1), IL-1â 0.45
Table 1 Characteristics of subjects undergoing bronchoalveolar lavage procedures B1 and
B2
B1 B2
Number (male/female) 32 (15/17) 24 (12/12)
Age (years)* 42 (18–60) 45 (18–59)
Transplant type (n)
Autologous peripheral blood stem cells 22 17
Autologous bone marrow 6 5
Allogeneic (sibling donor) 4 2
Diagnosis (n)
Breast cancer 9 6
Non-Hodgkin’s lymphoma 8 5
Hodgkin’s disease 5 4
Myeloma 3 3
Chronic myeloid leukaemia 3 2
Acute leukaemia 3 4
Aplastic anaemia 1 0
Blood count at time of lavage*
Haemoglobin (g/l) 109 (84–148) 102 (82–148)
White cells (×109/l) 4.2 (2.0–8.6) 0.2 (0.1–1.0)
Neutrophils (×109/l) 2.9 (0.1–7.5) 0.05 (0–0.5)
Platelets† (×109/l) 221 (17–768) 27 (6–46)
*Median (range).
†Before transfusion.
Table 2 Subjects with post-transplant lung disease and/or relevant respiratory histories: clinical details and cytokine production status
High cytokine
production?*
Subject no Post-transplant lung disease (days after SCT) Respiratory history (time before B1) TNFá GM-CSF
6 Hypoxia, collapsed middle lobe (day 7) Asthma, inhaled corticosteroids, recent mild exacerbation (3 weeks) Yes Yes
7 Pulmonary oedema, then pneumonia,Stenotrophomonas
maltophila isolated; fatal (day 14)
Current smoker Yes Yes
9 Pseudomonas aeruginosa pneumonia, adult respiratory
distress syndrome; fatal (day 10)
Chest infection (5 months) Yes Yes
10 Pneumonia, Candida albicans in BAL fluid (day 18) None Yes Yes
12 None Cough, green sputum (1 week) No No
19 Hypoxia, right basal consolidation (day 18) Current smoker; pneumonia (2 years) No Yes
21 Pseudomonas aeruginosa pneumonia (day 10) None No No
22 Breathlessness, fever, perihilar radiographic opacification
(day 166)
Current smoker Yes Yes
24 Cough, fever, bibasal radiographic opacification (day 68) Chest infection (13 months) No No
28 Cough, hypoxia, patchy radiographic opacification (day 0) Dry cough (2 weeks) Yes Yes
30 None Current smoker No Yes
36 None Asthma, low dose inhaled steroids No No
40 None Self-limiting dry cough (1 week) No No
45 None Untreated childhood TB, abnormal chest radiograph No No
47 None Current smoker No No
49 Fever, hypoxia, bibasal consolidation (day 13) Pneumonia (5 months) NA NA
52 Hypoxia, diVuse radiographic opacification, recovery with
corticosteroids (day 7)
Current smoker No No
54 None Pulmonary vasculitis (3 years, recurrent at 9 months) No No
*Pre-SCT (B1) AM cytokine production: TNFá >7 ng/106AM, GM-CSF >2 ng/106AM.
NA = not available.
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(0.09–1.2), IL-6 0.19 (0.04–0.49), IL-8 393
(148–507); no respiratory history (n=17):
TNFá 3.18 (1.6–6.1), GM-CSF 0.56 (0.07–
1.2), IL-1â 0.19 (0.09–1.2), IL-6 0.15 (0.03–
0.33), IL-8 502 (256–622), all p>0.2; fig 1).
Since both pre-SCT AM cytokine produc-
tion and respiratory history were related to
post-transplant lung disease, we were con-
cerned that these data could conceal a
subpopulation of high cytokine producers with
a relevant history. Categorical analysis showed
that the levels of TNFá and GM-CSF produc-
tion associated with a high risk of post-SCT
lung disease were also associated with a
relevant respiratory history. Of 15 B1 subjects
with a relevant history, five had TNFá produc-
tion of >7 ng/106 AM compared with one of 17
with no history of respiratory disease
(p=0.047, RR 5.7, 95% CI 0.7 to 43). Seven
B1 subjects with a relevant history had
GM-CSF production >2 ng/106 AM compared
with two with no history (p=0.03, RR 7.3, 95%
CI 2.6 to 21). We could not identify any
subsections of the broadly defined “respiratory
history” (such as cigarette smoking) that were
particularly associated with high TNFá or
GM-CSF production (table 2).
Pulmonary function tests performed a me-
dian of 32 days (range 7–88) before transplan-
tation showed no diVerences between subjects
who developed post-transplant lung disease
and those who did not (post-SCT lung disease
(n=11): mean (SD) FEV1 92 (19)% predicted,
FEV1/FVC 79 (10)%, TLC 91 (17)% pre-
dicted, TLCO 81 (13)% predicted, KCO 89
(14)% predicted; no lung disease (n=22): FEV1
102 (20)%, FEV1/FVC 82 (9)%, TLC 99
(14)%, TLCO 81 (19)%, KCO 87 (19)%; all
p>0.2.)
Discussion
Proinflammatory AM activity detectable be-
fore transplantation and positive findings in the
respiratory history were both associated with
lung disease following SCT. These associations
have not previously been described and, if con-
firmed in larger studies, could identify high risk
patients before transplantation with greater
confidence than other reported prognostic
markers.6 7 20 These are not independent asso-
ciations: many subjects who had increased AM
activity also had a relevant history. In these
cases the pathology reflected in the history
could have caused the increased AM activity, or
persistent proinflammatory AM behaviour
could have predisposed to both pre-transplant
and post-transplant lung disease.
An association between high pre-transplant
proinflammatory AM cytokine production and
subsequent lung disease is biologically plausi-
ble. The cytokines showing the association
(TNFá, GM-CSF and IL-6, plus IL-1â which
Table 3 Cytokine production by alveolar macrophages (AM), divided retrospectively according to subjects’ development of
lung disease after stem cell transplantation (SCT)
AM obtained before SCT (B1) AM obtained during post-SCT pancytopenia (B2)
Cytokine
No post-SCT lung
disease (n=22)
Post-SCT lung
disease (n=10) Significance
No post-SCT lung
disease (n=19)
Post-SCT lung
disease (n=5) Significance
TNFá 1.9 (1.0–4.6) 7.9 (1.1–8.4) p = 0.01* 1.9 (0.31–3.3) 4.6 (2.2–9.0) p = 0.07
GM-CSF 0.21 (0.07–0.79) 5.2 (0.72–8.3) p = 0.006† 0.11 (0.06–0.32) 1.2 (0.74–9.1) p = 0.01¶
IL-1â 0.18 (0.07–0.91) 0.95 (0.15–2.2) p = 0.06 0.18 (0.01–0.43) 0.13 (0.06–1.4) p = 0.6
IL-6 0.10 (0.02–0.29) 0.46 (0.13–1.23) p = 0.049‡ 0.07 (0.04–0.13) 0.13 (0.06–2.1) p = 0.2
IL-8 417 (204–533) 460 (298–805) p = 0.3 172 (90–334) 355 (238–777) p = 0.2
Values are medians (interquartile range) in ng/106 AM. *Median diVerence 3.4 (95% confidence interval (CI) 0.08 to 7.0). †Median
diVerence 4.4 (95% CI 0.47 to 7.5). ‡Median diVerence 0.3 (95% CI 0.0002 to 0.92). ¶Median diVerence 1.1 (95% CI 0.11 to 5.8).
Figure 1 (A) TNFá and (B) GM-CSF production by pre-transplant alveolar macrophages (AM): comparison between
subjects who developed post-transplant lung disease and those who did not. Horizontal lines = median values;Ä = subjects
with a relevant respiratory history; C = other subjects.
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showed a trend in that direction) have complex
interrelated functions in the initiation and
maintenance of inflammation. GM-CSF, in
particular, maintains a proinflammatory alveo-
lar environment21–23 which could predispose to
overt clinical disease in response to toxic or
infectious challenge. In contrast, we found no
relationship between IL-8 production and later
lung disease. This chemokine has a specific role
as a neutrophil chemoattractant in response to
injury, so our subjects studied before any insult
might not be expected to show diVering
levels.24 25
AM survive with little change in numbers
into the post-transplant pancytopenic phase,8 9
so the pre-transplant AM population has
continuing influence after SCT. Our data from
post-SCT pancytopenic subjects were weak-
ened by the exclusion of subjects who had
already developed lung disease at the time of
post-transplant BAL: this was done to avoid
the confounding eVects of new active disease.
Despite this, we found that high AM GM-CSF
production during pancytopenia was associ-
ated with later lung disease, and there was a
trend in this direction for TNFá. This supports
the hypothesis that there is an AM activation
pattern associated with lung disease, and that
this pattern persists after SCT.
We have not identified a reason for the
increased AM activation shown by some of our
subjects. The relationship between high cyto-
kine production and a history of pulmonary
infection or inflammation did not apply to all
high cytokine producers, and most of those
with a history did not show high production. A
further mechanism is needed to account for
persistent proinflammatory AM activity in a
minority of subjects: continuing subclinical or
unreported respiratory disease and genetic
variability are both possibilities.
Identification before transplantation of indi-
viduals at risk of post-transplant lung disease
would be clinically valuable, allowing the use of
alternative treatments or of conditioning regi-
mens with less pulmonary toxicity, and
prompting heightened surveillance for post-
SCT lung disease. Pulmonary function testing
is widely used in this context, and large studies
have shown associations between impaired
function and post-transplant lung disease.6 17 26
Our impression has been that mild impairment
of lung function is insuYciently specific for
clinical use in predicting post-SCT lung
disease, and our negative findings concerning
lung function support that view. This study
suggests that a positive respiratory history may
be a more significant marker of risk and that,
among those with a history, persistent AM
activation identifies a subgroup at very high
risk.
This work should be viewed as preliminary;
we cannot yet recommend that all candidates
for SCT should undergo assay of AM cytokine
production. Our population was too small to
allow comparisons with mortality, and was
heterogeneous in underlying disease, trans-
plant type, and conditioning regimen. In this
respect it was typical of reports from many
transplant centres, but the benefits of an
invasive technique should be proven in indi-
vidual patient groups to avoid unnecessary
procedures. Further work is therefore needed,
but this approach has the potential to reduce
the exposure of patients to the pulmonary side
eVects of stem cell transplantation.
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